Suppr超能文献

通过(3H)二氢麦角隐亭结合鉴定α-肾上腺素能受体。

Alpha-adrenergic receptor identification by (3H)dihydroergocryptine binding.

作者信息

Williams L T, Lefkowitz R J

出版信息

Science. 1976 May 21;192(4241):791-3. doi: 10.1126/science.4894.

Abstract

A radioactively labeled alpha-adrenergic antagonist, [3H]dihydroergocryptine, binds specifically to a site on rabbit uterine membranes. Binding is rapid, reaching equilibrium in less than 17 minutes at 25 degrees C. Adrenergic agonists compete for this binding site with an order of affinities identical to the pharmacological potency order of these agents as alpha-adrenergic agonists (epinephrine greater than norepinephrine greater than isoprotereonl). The (-) stereoisomers of epinephrine and norepinephrine are 30 times more potent in competing for the site than the corresponding (+) stereoisomers. alpha-Adrenergic antagonists, such as phentolamine and phenoxybenzamine, potently compete for the binding sites while the beta-adrenergic antagonist propranolol does not. Structural analogs of catecholamines that are devoid of alpha-adrenergic physiological activity do not compete for [3H]dihydroergocryptine binding sites. These data suggest that alpha-adrenergic receptors can be directly identified and studied by [3H]dihydroergocryptine binding.

摘要

一种放射性标记的α-肾上腺素能拮抗剂,[3H]二氢麦角隐亭,可特异性结合于兔子宫膜上的一个位点。结合迅速,在25℃下不到17分钟即可达到平衡。肾上腺素能激动剂竞争该结合位点,其亲和力顺序与这些药物作为α-肾上腺素能激动剂的药理效价顺序相同(肾上腺素>去甲肾上腺素>异丙肾上腺素)。肾上腺素和去甲肾上腺素的(-)立体异构体在竞争该位点时的效力比相应的(+)立体异构体强30倍。α-肾上腺素能拮抗剂,如酚妥拉明和酚苄明,能有效竞争结合位点,而β-肾上腺素能拮抗剂普萘洛尔则不能。缺乏α-肾上腺素能生理活性的儿茶酚胺结构类似物不竞争[3H]二氢麦角隐亭结合位点。这些数据表明,α-肾上腺素能受体可通过[3H]二氢麦角隐亭结合直接鉴定和研究。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验